{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:16Z","timestamp":1793320636439,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Corporation of North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022752","name":"MSD Sharp & Dohme GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116847","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:01:45Z","timestamp":1780531305000},"page":"116847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006\/IMMUNIB translational phase-2 study"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Ben Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Ruiz","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-293X","authenticated-orcid":false,"given":"Silke","family":"Marhenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Siebler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Lindig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schultheiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8101-8207","authenticated-orcid":false,"given":"Enrico N.","family":"De Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Karl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah-E.","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-4276","authenticated-orcid":false,"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2026.116847_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2026.116847_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","author":"Vogel","year":"2025","journal-title":"Ann Oncol J Eur Soc Med Oncol \/ ESMO"},{"issue":"2","key":"10.1016\/j.ejca.2026.116847_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"European Association for the Study of the","year":"2025","journal-title":"J Hepatol"},{"issue":"10360","key":"10.1016\/j.ejca.2026.116847_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"10126","key":"10.1016\/j.ejca.2026.116847_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ejca.2026.116847_bib6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116847_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"issue":"10492","key":"10.1016\/j.ejca.2026.116847_bib8","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2026.116847_bib9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116847_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10474","key":"10.1016\/j.ejca.2026.116847_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2026.116847_bib12","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","article-title":"Liquid biopsy epigenomic profiling for cancer subtyping","volume":"29","author":"Baca","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.ejca.2026.116847_bib13","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1158\/1078-0432.CCR-24-0466","article-title":"Detecting small cell transformation in patients with advanced egfr mutant lung adenocarcinoma through epigenomic cfDNA profiling","volume":"30","author":"El Zarif","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2026.116847_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114350","article-title":"Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma","volume":"43","author":"El Zarif","year":"2024","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.ejca.2026.116847_bib15","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejca.2026.116847_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.ejca.2026.116847_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"issue":"3","key":"10.1016\/j.ejca.2026.116847_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521746","article-title":"Real-world data for lenvatinib in hepatocellular carcinoma (elevator): a retrospective multicenter study","volume":"11","author":"Welland","year":"2022","journal-title":"Liver Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:47:48Z","timestamp":1783486068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"alternative-id":["S0959804926006283"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116847","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006\/IMMUNIB translational phase-2 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116847"}}